z-logo
open-access-imgOpen Access
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Author(s) -
Sabine Schmid,
Aurelius Omlin,
Celestia S. Higano,
Christopher J. Sweeney,
Nieves Martínez Chanzá,
Niven Mehra,
Malou C.P. Kuppen,
Himisha Beltran,
Vincenza Conteduca,
Daniel Vargas Pivato de Almeida,
Fernando Cotait Maluf,
William Oh,
CheKai Tsao,
Oliver Sartor,
Elisa M. Ledet,
Giuseppe Di Lorenzo,
Steven Yip,
Kim N.,
Diletta Bianchini,
Ugo De Giorgi,
Aaron R. Hansen,
Tomasz M. Beer,
Pernelle Lavaud,
Rafael MoralesBarrera,
Marcello Tucci,
Elena Castro,
Kostas Karalis,
Andries M. Bergman,
Mo Linh Le,
Ursina ZürrerHärdi,
Carmel Pezaro,
Hiroyoshi Suzuki,
Andrea Zivi,
Dirk Klingbiel,
Sämi Schär,
Silke Gillessen
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.21692
Subject(s) - prostate cancer , medicine , oncology , cohort , dna repair , population , chemotherapy , biomarker , cancer , gene , biology , genetics , environmental health
Key Points Question Is there a role for platinum-based treatment in molecularly selected patients with advanced prostate cancer? Findings In a case series of 508 patients, platinum-based therapy was associated with antitumor activity, especially among patients with known DNA repair gene aberrations. In patients with DNA repair gene aberrations, nearly half had a decrease in prostate-specific antigen levels of at least 50% and experienced soft tissue responses. Meaning In patients with prostate cancer and DNA repair gene aberrations, platinum-based therapy may be considered a treatment option.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom